Email Alert RSS
Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
Abstract
References
Related Articles
XIE Jing, WANG Huanling. Patient-centric Clinical Trials: A New Paradigm for Drug Development[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 849-853. DOI: 10.12290/xhyxzz.2021-0056
Citation: XIE Jing, WANG Huanling. Patient-centric Clinical Trials: A New Paradigm for Drug Development[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 849-853. DOI: 10.12290/xhyxzz.2021-0056
shu

Patient-centric Clinical Trials: A New Paradigm for Drug Development

  • 1.

    Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

  • 2.

    Clinical Pharmacology Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China

More Information
  • Corresponding author:

    WANG Huanling  Tel: 86-10-69158360, E-mail: wanghuanling@pumch.cn

  • Received Date: January 17, 2021
  • Accepted Date: April 21, 2021
  • Available Online: September 14, 2021
  • Issue Publish Date: November 29, 2021
    Graphical Abstract
    • Abstract
  • With the acceleration of innovative drugs launched in the market, clinical trials have become increasingly complex and costly. Integration of patients' perspective and engagement into the clinical research process is essential to the success of the trials, which leads to the emergence of the concept of patient-centric clinical trials. Compared to the conventional paradigm of clinical trials, patient-centric clinical trials have the potential to increase the feasibility of study protocol, to speed recruitment and execution, and to promote the success of trials. It calls for the institutions and investigators of clinical trials to be aware of and adapt to patient-centric initiatives. In this article, we highlight technologies and actions that can be used to enhance patients' engagement in the entire process of drug development, covering protocol development, trial conduction, and result publication.
    • FullText(HTML)
    • References (20)
  • [1]
    Sharma NS. Patient centric approach for clinical trials: Current trend and new opportunities[J]. Perspect Clin Res, 2015, 6: 134-138. DOI: 10.4103/2229-3485.159936
    [2]
    Smith MY, Benattia I. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization[J]. Drug Saf, 2016, 39: 779-785. DOI: 10.1007/s40264-016-0426-9
    [3]
    Dockendorf MF, Hansen BJ, Bateman KP, et al. Digitally Enabled, Patient-Centric Clinical Trials: Shifting the Drug Development Paradigm[J]. Clin Transl Sci, 2021, 14: 445-459. DOI: 10.1111/cts.12910
    [4]
    Babiker HM, Davis L, Larson K, et al. A Multidisciplinary Evaluation of Barriers to Enrolling Cancer Patients into Early Phase Clinical Trials: Challenges and Patient-centric Recommendations[J]. Expert Opin Investig Drugs, 2019, 28: 675-686. DOI: 10.1080/13543784.2019.1646726
    [5]
    Patalano F, Gutzwiller FS, Shah B, et al. Gathering Structured Patient Insight to Drive the PRO Strategy in COPD: Patient-Centric Drug Development from Theory to Practice[J]. Adv Ther, 2020, 37: 17-26. DOI: 10.1007/s12325-019-01134-x
    [6]
    Desai A, Warner J, Kuderer N, et al. Crowdsourcing a crisis response for COVID-19 in oncology[J]. Nat Cancer, 2020: 1-4. doi: 10.1038/s43018-020-0065-z.[Epubahead of print].
    [7]
    Day S, Mathews A, Blumberg M, et al. Broadening community engagement in clinical research: Designing and assessing a pilot crowdsourcing project to obtain community feedback on an HIV clinical trial[J]. Clin Trials, 2020, 17: 306-313. DOI: 10.1177/1740774520902741
    [8]
    Leiter A, Sablinski T, Diefenbach M, et al. Use of Crowdsourcing for Cancer Clinical Trial Development[J]. J Natl Cancer Inst, 2014, 106: dju258. http://www.onacademic.com/detail/journal_1000036697570210_e183.html
    [9]
    Lee YJ, Arida JA, Donovan HS. The application of crowdsourcing approaches to cancer research: a systematic review[J]. Cancer Med, 2017, 6: 2595-2605. DOI: 10.1002/cam4.1165
    [10]
    P Bateman K. The development of patient-centric sampling as an enabling technology for clinical trials[J]. Bioanalysis, 2020, 12: 971-976. DOI: 10.4155/bio-2020-0075
    [11]
    James CA, Barfield MD, Maass KF, et al. Will patient-centric sampling become the norm for clinical trials after COVID-19?[J]. Nat Med, 2020, 26: 1810. DOI: 10.1038/s41591-020-01144-1
    [12]
    Lamberti MJ, Awatin J. Mapping the Landscape of Patient-centric Activities Within Clinical Research[J]. Clin Ther, 2017, 39: 2196-2202. DOI: 10.1016/j.clinthera.2017.09.010
    [13]
    U.S. Department of Health and Human Services Food and Drug Administration. Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation. Draft Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders[EB/OL]. [2021-1-11]. https://www.fda.gov/media/139088/download.
    [14]
    Annapureddy N, Devilliers H, Jolly M. Patient-reported outcomes in lupus clinical trials with biologics[J]. Lupus, 2016, 25: 1111-1121. DOI: 10.1177/0961203316652494
    [15]
    冯仁田, 杨志清. 欧美临床试验文件中通俗化语言的应用[J]. 中国新药与临床杂志, 2021, 40: 356-361. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202105007.htm

    Feng RT, Yang ZQ. Application of plain language in clinical study documents in European and American[J]. Zhongguo Xinyao Yu Linchuang Zazhi, 2021, 40: 356-361. https://www.cnki.com.cn/Article/CJFDTOTAL-XYYL202105007.htm
    [16]
    Richards DP, Birnie KA, Eubanks K, et al. Guidance on authorship with and acknowledgement of patient partners in patient-oriented research[J]. Res Involv Engagem, 2020, 6: 38. DOI: 10.1186/s40900-020-00213-6
    [17]
    Arnstein L, Wadsworth AC, Yamamoto BA, et al. Patient involvement in preparing health research peer-reviewed publications or results summaries: a systematic review and evidence-based recommendations[J]. Res Involv Engagem, 2020, 6: 34. DOI: 10.1186/s40900-020-00190-w
    [18]
    Li CC, Dockendorf M, Kowalski K, et al. Population PK Analyses of Ubrogepant (MK-1602), a CGRP Receptor Antagonist: Enriching In-Clinic Plasma PK Sampling With Outpatient Dried Blood Spot Sampling[J]. J Clin Pharmacol, 2018, 58: 294-303. DOI: 10.1002/jcph.1021
    [19]
    Faulkner M, Alikhaani J, Brown L, et al. Exploring Meaningful Patient Engagement in ADAPTABLE (Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-term Effectiveness)[J]. Med Care, 2018, 56: S11-S15. DOI: 10.1097/MLR.0000000000000949
    [20]
    Marquis-Gravel G, Robertson H, Jones WS, et al. Streamlining the institutional review board process in pragmatic randomized clinical trials: challenges and lessons learned from the Aspirin Dosing: A Patient-centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) trial[J]. Trials, 2021, 22: 90. DOI: 10.1186/s13063-021-05026-w
    • Related Articles

  • Related Articles

    [1]JIA Chunyu, WANG Gangan, WANG Jiahui, CHEN Gang, ZHENG Ke, LI Xuemei. Correlation Between Neutrophil to Lymphocyte Ratio and eGFR in Diabetic Patients: A Cross-sectional Analysis Based on NHANES Data[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(2): 379-385. DOI: 10.12290/xhyxzz.2024-0908
    [2]LIANG Yan. Interpretation on the 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guidelines for the Management of Patients with Chronic Coronary Disease[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 312-319. DOI: 10.12290/xhyxzz.2024-0043
    [3]LIU Wanrong, TANG Hui, ZHOU Na, QIU Wei, LI Xiaoyuan, WANG Xiang, BAI Chunmei, ZHOU Jianfeng, ZHAO Lin. Incidence of COVID-19 in Patients with Tumor During the Omicron Pandemic[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(6): 1238-1245. DOI: 10.12290/xhyxzz.2023-0281
    [4]LIU Huan, HUANG Xiaoling, DAI Mengying, GUO Jiejie, GAO feng. Clinical Characteristics and Inflammatory Markers of Omicron BA.5.2 Variant Infection in Hospitalized Patients and Their Predictive Role in Disease Prognosis[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 1038-1045. DOI: 10.12290/xhyxzz.2023-0055
    [5]LI Wendao, GU Hao, WANG Wei, WU Runhui, SONG Hongmei. First Case Report of FOXN1 Haploinsufficiency in China and Literature Review[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 366-372. DOI: 10.12290/xhyxzz.2022-0040
    [6]HE Leren. Clinical Research Tools for Plastic Surgery: Introduction of the Patient Reported Outcome Measures and Their Application[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 383-386. DOI: 10.12290/xhyxzz.2022-0137
    [7]ZHAO Zhe, TANG Yan, ZHOU Jingya, CHEN Xiaoguang, ZHANG Lei, CHEN Limeng, YUAN Tao. Analysis of Clinical Manifestations and Drug Therapies of Gitelman Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 277-286. DOI: 10.12290/xhyxzz.2021-0180
    [8]Noyes' Knee Disorders: Surgery, Rehabilitation, Clinical Outcomes(2nd ed.)(2016)[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(1): 18-18.
    [9]MAIMAITI Nu-rong-gu-li, Hua-bing ZHANG, Xiao-ping XING. Clinical and Genetic Analysis of a Uyghur Patient with Gitelman's Syndrome[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(6): 427-431. DOI: 10.3969/j.issn.1674-9081.2015.06.006
    [10]Xu ZHANG, Yong-sheng TIAN, Xiao-wei CHEN, Hong JIANG. Mitochondrial 12S rRNA Mutations Related to Drug-induced Hearing Loss[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(2): 185-189. DOI: 10.3969/j.issn.1674-9081.2012.02.012

  • Cited by

    Periodical cited type(7)

    1. 方中坚，沈家辉，汪颖霞，张亮，樊玉录，朱思琪，邵蓉，邵明立. 以患者为中心的临床试验理念及发展趋势探讨. 中国新药杂志. 2024(13): 1356-1361 .
    2. 李多静，邢永发，吴哲颖，庄铭，王保和，张莉. 中医药临床疗效评价的研究进展与思考. 天津中医药. 2024(09): 1200-1205 .
    3. 吴清，孙超，吴大维，汤骐羽，贾硕鹏，唐玉，黄慧瑶，房虹，于锋，李宁. 肿瘤受试者对以患者为中心的药物临床试验的参与意愿及其影响因素调查. 肿瘤药学. 2024(06): 653-661 .
    4. 翟静波. 以患者为中心的中医药防治慢性病临床诊疗方案遴选与评价方法学框架. 中国循证医学杂志. 2023(04): 439-443 .
    5. 吴晓蕾，史梦龙，张晨瑶，马毓聪，杜亮，刘炳林，曹璐佳，张俊华. 以患者为中心药物研发相关概念介绍. 中国循证医学杂志. 2023(12): 1472-1477 .
    6. 朱琳，胡嘉浩，康琦，许艺帆，金春林. 患者报告结局在罕见病临床研究中的应用探讨. 世界临床药物. 2022(02): 124-129 .
    7. 刘灵娟，刘珂菲，张静，张一，陈宝安. 血液学“大专家.COM”平台建设之经验. 中国现代医生. 2022(30): 123-127+142 .

    Other cited types(2)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1706) PDF downloads (207) Cited by(9)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close